Cambridge Investment Research Advisors, Inc. Oncolytics Biotech Inc Transaction History
Cambridge Investment Research Advisors, Inc.
- $36.4 Billion
- Q3 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Oncolytics Biotech Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 24,771 shares of ONCY stock, worth $26,009. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,771
Previous 11,271
119.78%
Holding current value
$26,009
Previous $9,000
288.89%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ONCY
# of Institutions
58Shares Held
2.82MCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY383KShares$402,5130.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il382KShares$401,1530.0% of portfolio
-
Marshall Wace, LLP London, X0324KShares$340,1810.0% of portfolio
-
Seeds Investor LLC New York, NY258KShares$271,2210.08% of portfolio
-
Goldman Sachs Group Inc New York, NY209KShares$219,1320.0% of portfolio
About ONCOLYTICS BIOTECH INC
- Ticker ONCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 57,867,400
- Market Cap $60.8M
- Description
- Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...